Publikationen, an denen er mitarbeitet Mercedes Garayoa Berrueta (9)

2021

  1. Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression

    Cancers, Vol. 13, Núm. 6, pp. 1-26

2020

  1. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

    Haematologica

  2. Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma

    Cancers, Vol. 12, Núm. 10, pp. 1-20

2017

  1. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

    Haematologica, Vol. 102, Núm. 1, pp. 168-175

  3. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

    Haematologica, Vol. 102, Núm. 12, pp. 2113-2124

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2013

  1. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

    Blood, Vol. 122, Núm. 22, pp. 3591-3598

2008

  1. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

    Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225